Logo 1 Logo 2

Clinical Trial Details

Trial ID: L7149
Source ID: NCT01829477
Associated Drug: Tak-875
Title: Comparison of TAK-875 to Placebo as an Add-on to Glimepiride in Patients With Type 2 Diabetes
Acronym:
Status: TERMINATED
Study Results: YES
Results: https://ClinicalTrials.gov/show/NCT01829477/results
Conditions: Diabetes Mellitus, Type 2
Interventions: DRUG: TAK-875|DRUG: TAK-875 Placebo|DRUG: Glimepiride
Outcome Measures: Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24, The change in the value of glycosylated hemoglobin (the concentration of glucose bound to hemoglobin as a percent of the absolute maximum that can be bound) collected at week 24 relative to baseline., Baseline and Week 24 | Secondary: Percentage of Participants With HbA1c <7 % at Week 24., Week 24|Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, The change between the fasting plasma glucose value collected at week 24 or final visit relative to baseline., Baseline and Week 24
Sponsor/Collaborators: Sponsor: Takeda
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 33
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
Start Date: 2013-04
Completion Date: 2014-02
Results First Posted: 2016-06-01
Last Update Posted: 2016-06-01
Locations: Muscle Shoals, Alabama, United States|Phoenix, Arizona, United States|Fresno, California, United States|Long Beach, California, United States|National City, California, United States|North Hollywood, California, United States|Pismo Beach, California, United States|Lakewood, Colorado, United States|Boynton Beach, Florida, United States|Bradenton, Florida, United States|Coral Gables, Florida, United States|Miami, Florida, United States|North Miami Beach, Florida, United States|Orlando, Florida, United States|Pembroke Pines, Florida, United States|Tampa, Florida, United States|Augusta, Georgia, United States|Conyers, Georgia, United States|Chicago, Illinois, United States|Lexington, Kentucky, United States|Oxon Hill, Maryland, United States|Flint, Michigan, United States|Omaha, Nebraska, United States|Las Vegas, Nevada, United States|Nashua, New Hampshire, United States|Haddon Heights, New Jersey, United States|Rosedale, New York, United States|Morehead City, North Carolina, United States|Morganton, North Carolina, United States|Maumee, Ohio, United States|Hanleysville, Pennsylvania, United States|Uniontown, Pennsylvania, United States|Laurens, South Carolina, United States|Houston, Texas, United States|San Antonio, Texas, United States|Spring, Texas, United States|Tomball, Texas, United States|Manassas, Virginia, United States|Gabrovo, Bulgaria|Plovdiv, Bulgaria|Sofia, Bulgaria|Oakville, Ontario, Canada|Thornhill, Ontario, Canada|Toronto, Ontario, Canada|Budapest, Hungary|Godollo, Hungary|Kistelek, Hungary|Komarom, Hungary|Zalaegerszeg, Hungary|Bialystok, Poland|Gdansk, Poland|Grodzisk Mazowiecki, Poland|Kamieniec Zabkowicki, Poland|Lodz, Poland|Oswiecim, Poland|Poznan, Poland|Pulawy, Poland|Rzeszow, Poland|Zgierz, Poland|Baia Mare, Romania|Ploiesti, Romania|Timisoara, Romania|Banska Bystrica, Slovakia|Bratislava, Slovakia|Dolny Kubin, Slovakia|Levice, Slovakia|Lucenec, Slovakia|Pezinok, Slovakia|Svidnik, Slovakia
URL: https://clinicaltrials.gov/show/NCT01829477

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress